To investigate the effect of an anti-C5 treatment (and thereby the inhibition of terminal complement pathway) in obesity, HFD-fed Ldlr-/-.Leiden mice were treated with an anti-C5 antibody (HFD+BB5.1) or vehicle control (HFD+vehicle) from week 20 to the end of the study (week 32, Figure 1). The gene discussed is C5; the disease is obesity disorder.